FDA Renews Gene Therapy Experts Panel for Two Years
Published Date: 10/14/2026
Notice
Summary
The FDA is renewing its Cellular, Tissue, and Gene Therapies Advisory Committee for two more years, keeping it active until October 28, 2028. This committee helps the FDA make sure new cell, tissue, and gene therapies are safe and effective for people. If you’re involved in these cutting-edge treatments, this renewal means expert advice will keep guiding the FDA’s decisions without interruption.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-20988, Linear Hydraulic Cylinders From Canada, China, India, Mexico, and South Korea, Determinations
The U.S. government is looking into whether imports of linear hydraulic cylinders from Canada, China, India, Mexico, and South Korea are hurting American businesses by being sold unfairly cheap or getting government help. If confirmed, this could lead to new rules or tariffs to protect U.S. makers. Companies involved should watch for updates soon, as final decisions and possible changes are on the way.
Next: 2026-20990, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Requirements for Cosmetic Products
The FDA is updating how companies that make cosmetics must share info about their products, thanks to new rules from the 2022 Modernization of Cosmetics Regulation Act. This affects anyone responsible for cosmetic safety, labeling, and reporting problems. Comments on these info collection changes are open until November 13, 2026, with no new fees but clearer rules to keep cosmetics safe and honest.